Molecular Medicine

, Volume 17, Issue 9–10, pp 1119–1126 | Cite as

Tissue Factor-Dependent Chemokine Production Aggravates Experimental Colitis

  • Karla C. S. Queiroz
  • Cornelis van’t Veer
  • Yascha van den Berg
  • JanWillem Duitman
  • Henri H. Versteeg
  • Hella L. Aberson
  • Angelique P. Groot
  • Marleen I. Verstege
  • Joris J. T. H. Roelofs
  • Anje A. te Velde
  • C. Arnold Spek
Research Article


Tissue factor (TF) is traditionally known as the initiator of blood coagulation, but TF also plays an Important role In inflammatory processes. Considering the pivotal role of coagulation in inflammatory bowel disease, we assessed whether genetic ablation of TF limits experimental colitis. To this end, wild-type and TF-deficient (TFlow) mice were treated with 1.5% dextran sulfate sodium (DSS) for 7 d, and effects on disease severity, cytokine production and leukocyte recruitment were examined. Clinical and histological parameters showed that the severity of colitis was reduced in both heterozygous and homozygous TFlow mice compared with controls. Most notably, edema, granulocyte numbers at the site of inflammation and cytokine levels were reduced in TFlow mice. Although anticoagulant treatment with dalteparin of wild-type mice reduced local fibrin production and cytokine levels to a similar extent as in TFlow mice, it did not affect clinical and histological parameters of experimental colitis. Mechanistic studies revealed that TF expression did not influence the intrinsic capacity of granulocytes to migrate. Instead, TF enhanced granulocyte migration into the colon by inducing high levels of the granulocyte chemoattractant keratinocyte-derived chemokine (KC). Taken together, our data indicate that TF plays a detrimental role in experimental colitis by signal transduction-dependent KC production in colon epithelial cells, thereby provoking granulocyte influx with subsequent inflammation and organ damage.



We would like to thank Joost Daalhuisen, Marieke ten Brink and Danielle Kruijswijk for expert technical assistance. This work is supported by grant WO 06-02 of the Dutch Digestive Diseases Foundation (Maag Lever Darm Stichting [MLDS]).


  1. 1.
    Baumgart DC, Carding SR. (2007) Inflammatory bowel disease: cause and immunobiology. Lancet. 369:1627–40.CrossRefGoogle Scholar
  2. 2.
    Borensztajn K, Peppelenbosch MP, Spek CA. (2009) Coagulation factor Xa signaling: the link between coagulation and inflammatory bowel disease? Trends Pharmacol. Sci. 30:8–16.CrossRefPubMedGoogle Scholar
  3. 3.
    Strober W, Fuss I, Mannon P. (2007) The fundamental basis of inflammatory bowel disease. J. Clin. Invest. 117:514–21.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Cho JY, et al. (2007) Amelioration of dextran sulfate sodium-induced colitis in mice by oral administration of beta-caryophyllene, a sesquiterpene. Life Sci. 80:932–9.CrossRefPubMedGoogle Scholar
  5. 5.
    Bernstein C, et al. (2001) The incidence of deep venous thrombosis and pulmonary embolism among patients with inflammatory bowel disease: a population-based cohort study. Thromb. Haemost. 85:430–4.CrossRefPubMedGoogle Scholar
  6. 6.
    Talbot RW, et al. (1986) Vascular complications of inflammatory bowel disease. Mayo Clin. Proc. 61:140–5.CrossRefPubMedGoogle Scholar
  7. 7.
    Yoshida H, Granger DN. (2009) Inflammatory bowel disease: a paradigm for the link between coagulation and inflammation. Inflamm. Bowel Dis. 15:1245–55.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Graef V, Baggenstoss AH, Seaur WG. (1996) Venous thrombosis occurring in non-specific ulcerative colitis. Arch. Intern. Med. 17:377–82.Google Scholar
  9. 9.
    Danese S, et al. (2007) Inflammation and coagulation in inflammatory bowel disease: the clot thickens. Am. J. Gastroenterol. 102:174–86.CrossRefPubMedGoogle Scholar
  10. 10.
    Thompson NP, Wakefield AJ, Pounder RE. (1995) Inherited disorders of coagulation appear to protect against inflammatory bowel disease. Gastroenterology. 108:1011–5.CrossRefPubMedGoogle Scholar
  11. 11.
    Vrij AA, et al. (2001) Low molecular weight heparin treatment in steroid refractory ulcerative colitis: clinical outcome and influence on mucosal capillary thrombi. (2001) Scand. J. Gastroenterol. Suppl. 234:41–7.CrossRefGoogle Scholar
  12. 12.
    Gaffney PR, et al. (1995) Paradoxical response to heparin in 10 patients with ulcerative colitis. Am. J. Gastroenterol. 90:220–3.PubMedGoogle Scholar
  13. 13.
    Torkvist L, et al. (1999) Low molecular weight heparin as adjuvant therapy in active ulcerative colitis. Aliment Pharmacol. Ther. 13:1323–8.CrossRefPubMedGoogle Scholar
  14. 14.
    Folwaczny C, Wiebecke B, Loeschke K. (1999) Unfractioned heparin in the therapy of patients with highly active inflammatory bowel disease. Am. J. Gastroenterol. 94:1551–5.CrossRefPubMedGoogle Scholar
  15. 15.
    Bloom S, et al. (2004) Low molecular weight heparin (tinzaparin) vs. placebo in the treatment of mild to moderately active ulcerative colitis. Aliment Pharmacol. Ther. 19:871–8.CrossRefPubMedGoogle Scholar
  16. 16.
    Spek CA, ten Kate FJ, te Velde AA. (2007) Factor V Leiden and the etiology of inflammatory bowel disease. Thromb. Haemost. 98:670–3.CrossRefPubMedGoogle Scholar
  17. 17.
    Osterud B, Rapaport SI. (1977) Activation of factor IX by the reaction product of tissue factor and factor VII: additional pathway for initiating blood coagulation. Proc. Natl. Acad. Sci. U. S. A. 74:5260–4.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Nemerson Y. (1988) Tissue factor and hemostasis. Blood. 71:1–8.PubMedGoogle Scholar
  19. 19.
    Ruf W, Dorfleutner A, Riewald M. (2003) Specificity of coagulation factor signaling. J. Thromb. Haemost. 1:1495–503.CrossRefPubMedGoogle Scholar
  20. 20.
    Camerer E, et al. (2000) Binding of factor VIIa to tissue factor on keratinocytes induces gene expression. J. Biol. Chem. 275:6580–5.CrossRefPubMedGoogle Scholar
  21. 21.
    Johnson K, et al. (1998) Potential mechanisms for a proinflammatory vascular cytokine response to coagulation activation. J. Immunol. 160:5130–5.PubMedGoogle Scholar
  22. 22.
    Schoenmakers SH, et al. (2004) Tissue factor haploinsufficiency during endotoxin induced coagulation and inflammation in mice. J. Thromb.Haemost. 2:2185–93.CrossRefPubMedGoogle Scholar
  23. 23.
    Taylor FB Jr, et al. (1991) Lethal E. coli septic shock is prevented by blocking tissue factor with monoclonal antibody. Circ. Shock. 33:127–34.PubMedGoogle Scholar
  24. 24.
    Dackiw AP, et al. (1996) Prevention of endotoxin-induced mortality by antitissue factor immunization. Arch. Surg. 131:1273–8.CrossRefPubMedGoogle Scholar
  25. 25.
    Taylor FB, et al. (1998) Active site inhibited factor VIIa (DEGR VIIa) attenuates the coagulant and interleukin-6 and -8, but not tumor necrosis factor, responses of the baboon to LD100 Escherichia coli. Blood. 91:1609–15.PubMedGoogle Scholar
  26. 26.
    Anthoni C, et al. (2007) Tissue factor: a mediator of inflammatory cell recruitment, tissue injury, and thrombus formation in experimental colitis. J. Exp. Med. 204:1595–601.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Parry GC, et al. (1998) Low levels of tissue factor are compatible with development and hemostasis in mice. J. Clin. Invest. 101:560–9.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Myint KM, et al. (2006) RAGE control of diabetic nephropathy in a mouse model: effects of RAGE gene disruption and administration of low-molecular weight heparin. Diabetes. 55:2510–22.CrossRefPubMedGoogle Scholar
  29. 29.
    van Dop WA, et al. (2010) The absence of functional PI3Kgamma prevents leukocyte recruitment and ameliorates DSS-induced colitis in mice. Immunol. Lett. 131:33–9.CrossRefPubMedGoogle Scholar
  30. 30.
    Snoek SA, et al. (2010) Selective alpha7 nicotinic acetylcholine receptor agonists worsen disease in experimental colitis. Br. J. Pharmacol. 160:322–33.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Slofstra SH, et al. (2007) Gene expression profiling identifies C/EBPδ as a candidate regulator of endotoxin-induced disseminated intravascular coagulation. Am. J. Resp. Crit. Care Med. 176:602–9.CrossRefPubMedGoogle Scholar
  32. 32.
    Schoenmakers SH, et al. (2004) Tissue factor haploinsufficiency during endotoxin induced coagulation and inflammation in mice. J. Thromb. Haemost. 2:2185–93.CrossRefPubMedGoogle Scholar
  33. 33.
    Borensztajn K, Peppelenbosch MP, Spek CA. (2010) Coagulation factor Xa inhibits cancer cell migration via LIMK1-mediated cofilin inactivation. Thromb. Res. 125:e323–8.CrossRefPubMedGoogle Scholar
  34. 34.
    Bijlsma MF, et al. (2007) Sonic hedgehog induces transcription-independent cytoskeletal rearrangement and migration regulated by arachidonate metabolites. Cell Signal. 19:2596–604.CrossRefPubMedGoogle Scholar
  35. 35.
    Schaffner F, Ruf W. (2009) Tissue factor and PAR2 signaling in the tumor microenvironment. Arterioscler. Thromb. Vasc. Biol. 29:1999–2004.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Jiang X, et al. (2008) Formation of tissue factor-factor VIIa-factor Xa complex induces activation of the mTOR pathway which regulates migration of human breast cancer cells. Thromb. Haemost. 100:127–33.CrossRefPubMedGoogle Scholar
  37. 37.
    Brown PW, Bargen J, Weber HA. (1934) Chronic inflammatory lesions of the small intestine (regional enteritis). Am. J. Dig. Dis. 1:426–31.CrossRefGoogle Scholar
  38. 38.
    Feagan BG, et al. (2005) Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. N. Engl. J. Med. 352:2499–507.CrossRefPubMedGoogle Scholar
  39. 39.
    Targan SR, et al. (2007) Natalizumab for the treatment of active Crohncs disease: results of the ENCORE Trial. Gastroenterology. 132:1672–83.CrossRefPubMedGoogle Scholar
  40. 40.
    Osterud B. (2010) Tissue factor expression in blood cells. Thromb. Res. 125 Suppl 1:S31–4.CrossRefPubMedGoogle Scholar
  41. 41.
    Shea-Donohue T, et al. (2008) Mice deficient in the CXCR2 ligand, CXCL1 (KC/GRO-alpha), exhibit increased susceptibility to dextran sodium sulfate (DSS)-induced colitis. Innate Immun. 14:117–24.CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Chien-Huang Lin, et al. (2006) c-Src mediates thrombin-induced NF-κB activation and IL-8/CXCL8 expression in lung epithelial cells. J. Immunol. 177:3427–38.CrossRefGoogle Scholar
  43. 43.
    Lin CH, et al. (2011) Thrombin induces NF-kappaB activation and IL-8/CXCL8 expression in lung epithelial cells by a Rac1-dependent PI3K/Akt pathway. J. Biol. Chem. 286:10483–94.CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Izzo RS, et al. (1992) Interleukin-8 and neutrophil markers in colonic mucosa from patients with ulcerative colitis. Am. J. Gastroenterol. 87:1447–52.PubMedGoogle Scholar
  45. 45.
    Mazzucchelli L, et al. (1994) Expression of interleukin-8 gene in inflammatory bowel disease is related to the histological grade of active inflammation. Am. J. Pathol. 144:997–1007.PubMedPubMedCentralGoogle Scholar
  46. 46.
    Schuerer-Maly CC, et al. (1993) Interleukin-1 and experimental gastric ulcer healing in the rat. J. Physiol. Pharmacol. 44:23–9.PubMedGoogle Scholar
  47. 47.
    Demetz G, et al. (2010) Tissue factor-factor VIIa complex induces cytokine expression in coronary artery smooth muscle cells. Atherosclerosis. 212:466–71.CrossRefPubMedGoogle Scholar
  48. 48.
    Wang X, Gjernes E, Prydz H. (2002) Factor VIIa induces tissue factor-dependent up-regulation of interleukin-8 in a human keratinocyte line. J. Biol.Chem. 277:23620–6.CrossRefPubMedGoogle Scholar
  49. 49.
    Hjortoe GM, et al. (2004) Tissue factor-factor VIIa-specific up-regulation of IL-8 expression in MDA-MB-231 cells is mediated by PAR-2 and results in increased cell migratiom. Blood. 103:3029–37.CrossRefPubMedPubMedCentralGoogle Scholar
  50. 50.
    Wang H, et al. (2010) Proteinase-activated receptors induce interleukin-8 expression by intestinal epithelial cells through ERK/RSK90 activation and histone acetylation. FASEB J. 24:1971–80.CrossRefPubMedGoogle Scholar
  51. 51.
    Tanaka Y, et al. (2008) PAR2 triggers IL-8 release via MEK/ERK and PI3-kinase/Akt pathways in GI epithelial cells. Biochem. Biophys. Res. Commun. 377:622–6.CrossRefPubMedGoogle Scholar
  52. 52.
    Tahara T, et al. (2009) Promoter methylation of protease-activated receptor (PAR2) is associated with severe clinical phenotypes of ulcerative colitis (UC). Clin. Exp. Med. 9:125–30.CrossRefPubMedGoogle Scholar
  53. 53.
    Hyun E, et al. (2008) Protease-activated receptor-2 activation: a major actor in intestinal inflammation. Gut. 57:1222–9.CrossRefPubMedGoogle Scholar
  54. 54.
    Hyun E, et al. (2010) Contribution of bone marrow-derived cells to the pro-inflammatory effects of protease-activated receptor-2 in colitis. Inflamm. Res. 59:699–709.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© The Feinstein Institute for Medical Research 2011

Authors and Affiliations

  • Karla C. S. Queiroz
    • 1
  • Cornelis van’t Veer
    • 1
  • Yascha van den Berg
    • 2
  • JanWillem Duitman
    • 1
  • Henri H. Versteeg
    • 2
  • Hella L. Aberson
    • 1
  • Angelique P. Groot
    • 1
  • Marleen I. Verstege
    • 3
  • Joris J. T. H. Roelofs
    • 4
  • Anje A. te Velde
    • 3
  • C. Arnold Spek
    • 1
  1. 1.Center for Experimental and Molecular MedicineAcademic Medical CenterAmsterdamThe Netherlands
  2. 2.Einthoven Laboratory for Experimental Vascular MedicineLeiden University Medical CenterLeidenThe Netherlands
  3. 3.Tytgat Institute for Liver and Intestinal Research, Academic Medical CenterUniversity of AmsterdamAmsterdamThe Netherlands
  4. 4.Department of Pathology, Academic Medical CenterUniversity of AmsterdamAmsterdamThe Netherlands

Personalised recommendations